Dongbao Bio disclosed its 2026 semi-annual report. In the first half, total operating revenue reached 415 million yuan, up 12.37% year on year. Net profit attributable to the parent company was 37.404 million yuan, up 1.18% year on year. Net profit after deducting non-recurring items was 33.6014 million yuan, up 0.50% year on year. Net cash flow from operating activities was 54.5212 million yuan, up 8.41% year on year. Basic earnings per share were 0.063 yuan, and the weighted average return on equity was 2.15%. Based on the closing price on August 21, the company's price-to-earnings ratio on a trailing twelve-month basis was about 57.11 times, its price-to-book ratio on a latest-filing basis was about 1.78 times, and its price-to-sales ratio on a trailing twelve-month basis was about 3.96 times. The company is mainly engaged in the research, development, production and sales of gelatin, collagen, hollow capsules and related derivative products.
Baotou Dongbao Bio-Tech Co LtdFirst-half 2026 net profit rose 1.18% year on year, with revenue up 12.37%.
